Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma.
Anticancer Res
; 38(7): 4027-4034, 2018 Jul.
Article
in En
| MEDLINE
| ID: mdl-29970527
ABSTRACT
BACKGROUND:
There are few efficacy and toxicity data on sorafenib for patients treated for hepatocellular carcinoma (HCC) who are not Caucasian or Asian. MATERIALS ANDMETHODS:
A retrospective analysis was carried out on 67 patients treated with sorafenib for advanced HCC at an urban referral center. Patients were categorized by race, age, sex, status, stage, and dose. Primary outcomes were time to progression (TTP), toxicity, and treatment discontinuation by race.RESULTS:
African-Americans and Caucasians had significantly shorter TTP than patients of other races (Hispanic, Asian, and unidentified) [African-Americans hazard ratio (HR)=5.01, p=0.0068; Caucasians HR=8.25, p=0.0008). There were no significant differences in time to toxicity (p=0.99). Caucasians had the shortest time to therapy discontinuation (p=0.0298). TTP was shorter for males (HR=3.51, p=0.028), and longer for patients experiencing toxicity (HR=0.47, p=0.046).CONCLUSION:
Among patients treated with sorafenib for advanced HCC, non African-American/non-Caucasian race, female sex, and toxicity were associated with significantly longer time to progression.Key words
Full text:
1
Database:
MEDLINE
Therapeutic Methods and Therapies TCIM:
Terapias_biologicas
/
Aromoterapia
Main subject:
Phenylurea Compounds
/
Niacinamide
/
Carcinoma, Hepatocellular
/
Liver Neoplasms
/
Antineoplastic Agents
Type of study:
Observational_studies
/
Risk_factors_studies
Language:
En
Journal:
Anticancer Res
Year:
2018
Type:
Article
Affiliation country:
United States